Literature DB >> 10724052

Postthrombotic syndrome after hip or knee arthroplasty: a cross-sectional study.

J S Ginsberg1, F Turkstra, H R Buller, B MacKinnon, D Magier, J Hirsh.   

Abstract

BACKGROUND: Although the incidence of the postthrombotic syndrome (PTS) has been addressed in patients with symptomatic deep vein thrombosis (DVT), less information is available on the incidence in patients who develop asymptomatic DVT after major hip or knee arthroplasty.
OBJECTIVES: To determine whether symptomatic PTS occurs more frequently in patients who develop DVT after hip or knee arthroplasty than those who are free of DVT and to provide an estimate of the incidence of PTS in patients who had undergone major hip or knee arthroplasty and had proximal DVT, distal (calf) DVT, or no DVT. DESIGN AND
SETTING: A cross-sectional study conducted at the Hamilton Health Sciences Corporation, Hamilton, Ontario, and the Academic Medical Centre, Amsterdam, the Netherlands. SUBJECTS AND METHODS: Two hundred fifty-five subjects who had undergone major hip or knee arthroplasty 2 to 7 years previously and had routine predischarge venography showing proximal DVT (n = 25), distal DVT (n = 66), or no DVT (n = 164) were enrolled from March 1993 through December 1998. The presence of symptomatic PTS confirmed by the presence of objectively confirmed venous valvular incompetence was ascertained.
RESULTS: The rates of PTS were low and not significantly different among the 3 subgroups: 1 (4.0%, 95% confidence interval [CI] = 0.1%-20.4%) of 25 patients with proximal DVT, 4 (6.1%, 95% CI = 1.7%-14.8%) of 66 patients with distal DVT, and 7 (4.3%, 95% CI = 1.7%-8.6%) of 164 patients with no DVT.
CONCLUSIONS: Symptomatic PTS is an uncommon complaint after major hip or knee arthroplasty. Patients who develop postoperative proximal or distal DVT and who receive 6 to 12 weeks of anticoagulant therapy are not predisposed to PTS.

Entities:  

Mesh:

Year:  2000        PMID: 10724052     DOI: 10.1001/archinte.160.5.669

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  19 in total

1.  Prevention of post-discharge venous thromboembolism in patients with rheumatoid arthritis undergoing knee or hip arthroplasty: a continuing matter of debate.

Authors:  M T Nurmohamed; B A Dijkmans; B A Dijkmans
Journal:  Ann Rheum Dis       Date:  2001-10       Impact factor: 19.103

2.  Value-of-information analysis to reduce decision uncertainty associated with the choice of thromboprophylaxis after total hip replacement in the Irish healthcare setting.

Authors:  Laura McCullagh; Cathal Walsh; Michael Barry
Journal:  Pharmacoeconomics       Date:  2012-10-01       Impact factor: 4.981

3.  Cost-effectiveness of extended prophylaxis with fondaparinux compared with low molecular weight heparin against venous thromboembolism in patients undergoing hip fracture surgery.

Authors:  Jonas Lundkvist; David Bergqvist; Bengt Jönsson
Journal:  Eur J Health Econ       Date:  2007-01-16

Review 4.  The post-thrombotic syndrome: the forgotten morbidity of deep venous thrombosis.

Authors:  Susan R Kahn
Journal:  J Thromb Thrombolysis       Date:  2006-02       Impact factor: 2.300

5.  Thromboembolic disease after knee arthroplasty is rare in Southern Iran.

Authors:  G Hossain Shahcheraghi; Mahzad Javid; Mohammad M Arasteh
Journal:  J Orthop       Date:  2014-01-31

6.  Incidence of postthrombotic syndrome in patients undergoing primary total hip arthroplasty for osteoarthritis.

Authors:  Steven J Fitzgerald; Christopher M McAndrew; Matthew J Kraay; Victor M Goldberg
Journal:  Clin Orthop Relat Res       Date:  2011-02       Impact factor: 4.176

7.  A cost-effectiveness analysis of fondaparinux sodium compared with enoxaparin sodium as prophylaxis against venous thromboembolism: use in patients undergoing major orthopaedic surgery.

Authors:  Sean D Sullivan; Bruce L Davidson; Susan R Kahn; James E Muntz; Gerry Oster; Gary Raskob
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 8.  Measuring the outcomes and pharmacoeconomic consequences of venous thromboembolism prophylaxis in major orthopaedic surgery.

Authors:  Sean D Sullivan; Susan R Kahn; Bruce L Davidson; Lars Borris; Patrick Bossuyt; Gary Raskob
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 9.  Incidence and cost burden of post-thrombotic syndrome.

Authors:  Aneel A Ashrani; John A Heit
Journal:  J Thromb Thrombolysis       Date:  2009-02-18       Impact factor: 2.300

Review 10.  Contemporary issues in the prevention and management of postthrombotic syndrome.

Authors:  Sara R Vazquez; Andrew Freeman; Ryan C VanWoerkom; Matthew T Rondina
Journal:  Ann Pharmacother       Date:  2009-09-08       Impact factor: 3.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.